2,013 reports of this reaction
4.6% of all AFLIBERCEPT reports
#2 most reported adverse reaction
VISUAL IMPAIRMENT is the #2 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 2,013 FDA adverse event reports linking AFLIBERCEPT to VISUAL IMPAIRMENT. This represents approximately 4.6% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is moderately reported among AFLIBERCEPT users, representing a notable but not dominant share of adverse events.
In addition to visual impairment, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 2,013 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 4.6% of all adverse event reports for AFLIBERCEPT, making it one of the most commonly reported side effect.
If you experience visual impairment while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.